Oxybutynin Re-examined as a Potential Low-Cost Treatment for Hot Flashes

Oxybutynin, a decades-old, low-cost antimuscarinic drug long used in Brazil’s public health system for overactive bladder, is being re-examined as a treatment for hot flashes. A randomized trial in men on androgen deprivation therapy showed a statistically significant reduction of 6.89 hot flashes per day versus 2.15 on placebo — but experts urge dose caution.

Hot flashes disrupt sleep in up to 80% of women during the menopausal transition and a similar proportion of men receiving androgen deprivation therapy for prostate cancer. For patients who cannot take estrogen — those with hormone-dependent cancers or high cardiovascular risk — the options have been limited.

Now, Medscape reported this week, a narrative review presented at the 20th World Congress on Menopause in Rio de Janeiro is reviving debate about whether an old bladder drug can fill that gap.

Medscape reported the details of that argument and the expert pushback around it.

Oxybutynin Reduces Hot-Flash Frequency as an off-Label Treatment

  • Oxybutynin is an approved bladder medication, not an approved hot-flash treatment — using it for flashes is off-label under the regulations of Brazil’s National Health Surveillance Agency (Anvisa) and foreign regulatory agencies.
  • Trials show real reductions in hot-flash frequency, but the doses that help flashes (2.5–5 mg twice daily) are generally too low to control overactive bladder in adults.
  • Hormone therapy remains the first-line treatment when it is medically safe; oxybutynin is a secondary option reserved for specific cases.

What the ASCO Trial Actually Measured

The strongest new evidence comes from the randomized phase 2 Alliance A222001 trial, presented at the American Society of Clinical Oncology annual meeting and published in the Journal of Clinical Oncology. Men receiving oxybutynin 5 mg twice daily had a reduction of 6.89 hot flashes per day, compared with 2.15 per day on placebo — a statistically significant difference.

Earlier trials point in the same direction. A randomized study of the 15 mg extended-release formulation found a reduction of 9.48 episodes per day versus 4.69 with placebo, according to data indexed on PubMed. A separate retrospective study published in Menopause reported a 70% response rate in patients with refractory cancer.

Trial / formulation Oxybutynin dose Reduction (drug) Reduction (placebo)
Alliance A222001 (ASCO) 5 mg twice daily 6.89 flashes/day 2.15/day
Extended-release randomized trial 15 mg/day 9.48 episodes/day 4.69/day
Multicenter trial (immediate release) 2.5 mg and 5 mg twice daily Significant reduction from week 1 —

Why the Dose Gap Undermines the “Dual Benefit”

The Fiocruz review’s appeal rests on a theoretical overlap: one drug, one dose range, two highly prevalent complaints. Varanda told Medscape the intent was synthesis, not invention.

Urologists are skeptical of that overlap.

Varanda herself acknowledged the limitation: none of the randomized trials required a diagnosis of overactive bladder or assessed urinary outcomes.

The Side-Effect Ledger Patients Should Weigh

Oxybutynin is a nonselective muscarinic antagonist, blocking M1 through M5 receptors throughout the body. Because it is a highly lipophilic tertiary amine, it crosses the blood-brain barrier — meaning its anticholinergic effects reach the central nervous system, not just the bladder and sweat glands.

The numbers are concrete. In a study of the extended-release formulation, dry mouth (xerostomia) affected 52.1% of participants taking 15 mg. In the Leon-Ferre trial, dry mouth occurred in 33% of participants on 5 mg twice daily and 21% on 2.5 mg twice daily.

Riccetto told Medscape that dropout from overactive bladder treatment due to anticholinergic effects exceeds 80% after 12 months, and warned that combining oxybutynin with GLP-1 receptor agonists may worsen constipation and gastrointestinal bloating because both slow gastric emptying.

In older adults, the concern is cognitive: prolonged acetylcholine blockade is associated with cognitive decline, memory loss, drowsiness, and loss of balance.

For men on androgen deprivation therapy, urologic oncologist Fernando Korkes, MD, PhD, head of the Division of Urologic Oncology at the Faculdade de Medicina do ABC and coordinator of the Department of Uro-Oncology of the Brazilian Society of Urology, flagged a different risk: acute urinary retention. Assessment of postvoid residual urine before starting the drug, he said, remains mandatory.

Risks for Older Adults and Specific Patient Groups

  • Older adults: Anticholinergic burden raises the risk of cognitive impairment, drowsiness, and nocturnal falls; experts cited by Medscape recommend limiting duration and monitoring cognition.
  • Men on androgen deprivation therapy with enlarged prostates: Reduced detrusor contractility can cause acute urinary retention — a postvoid residual urine check should precede treatment.
  • Patients on GLP-1 receptor agonists: Combined gastric slowing may amplify constipation and bloating.
  • Anyone with untreated moderate-to-severe overactive bladder: The hot-flash dose of 2.5 mg twice daily is, per Riccetto’s assessment, practically ineffective for adult urinary urgency.

Cost, Access, and What Comes Next

By contrast, fezolinetant (Veoza) — the selective neurokinin 3 receptor antagonist that acts on KNDy neurons in the hypothalamus to restore thermoregulatory control without estrogenic or anticholinergic activity — received Anvisa marketing authorization in June 2026 for moderate-to-severe vasomotor symptoms, but its liver-monitoring requirements and high estimated cost may limit access through private insurance and SUS.

The evidence gap that matters most remains open. Results from the British BLUSH clinical trial are expected in 2027, but data directly comparing oxybutynin with venlafaxine do not yet exist. Until they do, experts recommend starting at the lowest effective dose — 2.5 mg/d, administered in two divided doses — monitoring for dry mouth and constipation, and never assuming the flash dose will treat the bladder.

References

  • Alliance A222001 randomized phase 2 trial, Journal of Clinical Oncology — doi.org/10.1200/JCO-25-01486
  • Journal of Clinical Oncology full-text archive — PMC12871868
  • Retrospective oxybutynin study, Menopause — doi.org/10.1097/01.gme.0000243574.01441.3e
  • Extended-release oxybutynin randomized trial — PubMed 27760081
  • Medscape Portuguese edition reporting from the 20th World Congress on Menopause, Rio de Janeiro (story by Daniela Barros).

Oxybutynin is not approved for the treatment of hot flashes; any use for this indication must be guided by a qualified physician.

Photo of author

Health Desk

Health Desk at Archyde.

Maison de Santé Ducélia Brings Multidisciplinary Care to Castellane

Henry Patten Criticises ATP Chairman and CEO for Trophy Presentation Absence